• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·NECLIFE.NS
Share

Nectar Lifesciences Limited Stocks

₹ 10.98Last Updated 18.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 22.25M

₹ 10.98
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, underval

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.09.2026 20:59

Laptop with On-Device AI: Google Announces Release Date and Prices for the First Googlebooks

21.09.2026 20:30

Turkey may consolidate the assets of closed-end funds into a pool to make payments to investors

21.09.2026 20:13

AMD's market capitalization exceeded $1 trillion for the first time

21.09.2026 19:01

"Crypto Spring Has Arrived, Crocuses Are Blooming": Bitcoin Hits an 8-Month High

21.09.2026 18:38

The second control tower system failure in two weeks led to flight delays in Britain

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026